BioCentury
ARTICLE | Clinical News

Aradigm's Linhaliq under EMA review for lung infection

April 6, 2018 5:46 PM UTC

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections.

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm under a 2013 deal. Linhaliq is a dual-release product consisting of a liposomal-encapsulated form of ciprofloxacin, a DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation...

BCIQ Company Profiles

Aradigm Corp.

Grifols S.A.

BCIQ Target Profiles

DNA gyrase